Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETHEMA LAM07: Risk-Adapted Treatment with Gemtuzumab Ozogamicin in AML
NCT01041040Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2007
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Started Oct 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01041040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01041040.